Comparative Pharmacology
Head-to-head clinical analysis: CHANTIX versus NICOTINE POLACRILEX ORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHANTIX versus NICOTINE POLACRILEX ORAL.
CHANTIX vs NICOTINE POLACRILEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at α4β2 nicotinic acetylcholine receptors; also full agonist at α7 nicotinic receptors. Reduces nicotine craving and withdrawal symptoms while blocking nicotine's reinforcing effects.
Nicotine polacrilex acts as a nicotinic acetylcholine receptor agonist, binding to α4β2 receptors in the ventral tegmental area and mediating dopamine release in the nucleus accumbens, which reduces withdrawal symptoms and cravings by providing a lower and slower peak of nicotine compared to smoking.
1 mg orally twice daily after starting a 1-week titration: days 1-3: 0.5 mg once daily; days 4-7: 0.5 mg twice daily; day 8 onward: 1 mg twice daily.
2 mg or 4 mg lozenge or gum as needed up to 20 lozenges or pieces of gum per day; typical dosing: 1 lozenge or piece of gum every 1-2 hours while awake, up to 12 per day. For smoking cessation, initial dose based on smoking habits: if first cigarette within 30 minutes of waking, use 4 mg; if >30 minutes, use 2 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours. Clinical context: Steady-state is achieved within 4 days; significant accumulation occurs in renal impairment (creatinine clearance <30 mL/min), requiring dose adjustment.
The terminal elimination half-life of nicotine is approximately 2 hours (range 1-4 hours) after intravenous administration or smoking, but after polacrilex gum use, absorption is slower and half-life may be slightly prolonged due to continued absorption. Clinical context: short half-life necessitates frequent dosing to maintain levels for smoking cessation.
Renal: 81% unchanged, 8% as metabolites; Fecal: <10% (as metabolites); Biliary: minimal.
Nicotine and its metabolites are primarily excreted renally. About 10-20% of nicotine is excreted unchanged in urine, with the remainder as metabolites, mainly cotinine. Urinary pH affects excretion; acidic urine increases clearance. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Smoking cessation aid
Smoking cessation aid